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ABSTRACT
Mesenchymal stem cells (MSCs) are a promising therapy for immune-mediated and inflammatory disor-
ders, because of their potent immunomodulatory properties. In this study, we investigated the use of
fresh, autologous, adipose-derivedMSCs (ASCs) for feline chronic gingivostomatitis (FCGS), a chronic, de-
bilitating, idiopathic, oral mucosal inflammatory disease. Nine cats with refractory FCGSwere enrolled in
this pilot study. Each cat received 2 intravenous injections of 20 million autologous ASCs, 1 month apart.
Oral biopsies were taken before and at 6months after the first ASC injection. Blood immune cell subsets,
serum protein, and cytokine levels weremeasured at 0, 1, 3, and 6months after treatment to assess im-
munomodulatory effects. Seven of the 9 cats completed the study. Five cats responded to treatment by
either complete clinical remission (n = 3) or substantial clinical improvement (n = 2). Two cats were non-
responders. Cats that responded to treatmentalsoexhibited systemic immunomodulationdemonstrated
by decreased numbers of circulating CD8+ T cells, a normalization of the CD4/CD8 ratio, decreased neu-
trophil counts, and interferon-g and interleukin (IL)-1b concentration, and a temporary increase in serum
IL-6 and tumor necrosis factor-a concentration. No clinical recurrence has occurred following complete
clinical remission (follow-up of 6–24 months). In this study, cats with <15% cytotoxic CD8 T cells with
low expression of CD8 (CD8lo) cells were 100% responsive to ASC therapy, whereas cats with >15% CD8lo
cells were nonresponders. The relative absence of CD8lo cells may be a biomarker to predict response to
ASC therapy, andmay shed light on pathogenesis of FCGS andmechanisms by which ASCs decrease oral
inflammation and affect T-cell phenotype. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:75–86
SIGNIFICANCE
This study is the first to demonstrate the safety and efficacy of fresh, autologous, adipose-derived stem
cell systemic therapy for a naturally occurring, chronic inflammatory disease in cats. The findings dem-
onstrate that this therapy resulted in completeclinical andhistological resolutionor reduction in clinical
disease severity and immune modulation in most cats. This study also identified a potentially useful
biomarker that could dictate patient enrollment and shed light on immune modulation mechanism.
As a naturally occurring animal model, FCGS also provides a strategic platform for potentially translat-
able therapy for the treatment of human oral inflammatory disease.
INTRODUCTION
Immune-mediated, oral mucosal inflammatory dis-
eases are prevalent in thehumanpopulation and in-
clude oral lichen planus, stomatitis, pemphigus, and
pemphigoid [1,2].Thesedisorderscausepainfulmu-
cosal lesions thatmarkedly reduce quality of life and
often require long-term immunosuppressive ther-
apywith significant associated risks and side effects.
The pathogenesis of these diseases is complex and
heterogeneous, but consistently involves tissue infil-
tration primarily by activated effector T and B cells,
with a skew toward a Th1 phenotype [3–5].
Naturally occurring diseases in client-owned
animal species serveasusefulanimalmodelsofhu-
man disease, as they reflect the complex genetic,
environmental, and physiologic variation present
in outbred populations. Feline chronic gingivosto-
matitis (FCGS) is a severe, idiopathic, oral inflam-
matory disease of cats that is estimated to affect
0.7%–10% of the general cat population [6–10].
Clinical signs are moderate to severe oral pain
and discomfort, including inappetence, reduced
grooming, weight loss, and hypersalivation [7, 8,
11]. FCGScanbedebilitating, andseverely affected
cats are often euthanized. Approximately 70% of
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cats respond to the current standard of care for FCGS, which is
full-mouth or near full-mouth tooth extraction. The remaining
30% of cats do not respond to tooth extraction and require life-
long therapy with antibiotics, corticosteroids, and pain medica-
tion (refractory FCGS) [7]. Spontaneous disease resolution has
not been reported in FCGS-affected cats. The pathogenesis of
FCGS is poorly understood but is thought to be due to the host
immune system responding inappropriately to chronic oral an-
tigenic stimulation secondary to underlying oral disease or clin-
ical or subclinical viral infections [11–14].
Adult mesenchymal stromal/stem cells (MSCs) are adher-
ent, fibroblast-like, multipotent stem cells [15, 16] that can be
isolated from multiple tissue types, including adipose tissue.
Adipose-derived MSCs (ASCs) have been isolated from humans
and several domestic animal species, including cats [17–23]. Au-
tologous ASCs are nonimmunogenic, safe in people and animals,
and have been used clinically in horses and people formore than
8yearswithno significant adverse reactions reportedother than
transient fever in people, occasional transfusion reactions in
cats, and self-resolving inflammatory flares in horses [22, 24,
25]. MSCs’ regenerative ability is attributed in part to their abil-
ity to modulate both innate and adaptive immune responses
[26–30]. MSCs inhibit T-cell proliferation, alter B-cell function,
downregulate MHC II on antigen-presenting cells, and inhibit
dendritic cell maturation and differentiation [26, 27, 29, 30].
MSCs are being used in phase I–III human clinical trials for in-
flammatory diseases including Crohn disease and graft versus
host disease with variably promising results [26, 31–33]. Like
the mentioned human inflammatory mucosal lesions, FCGS is
characterized by CD8 T-cell inflammation and a dysregulated im-
mune response [8, 9]. The ability of MSCs to inhibit T-cell prolif-
eration and induce T-cell anergy suggested that FCGS may be a
promising disease target for MSC therapy and a possible animal
model that mimics chronic human oral lesions.
The purpose of this study was to evaluate the clinical, histo-
pathologic, and immunologic effects resulting from systemic ad-
ministration of fresh, autologous ASCs in a cohort of cats affected
by FCGS that did not respond to previous conventional therapy.
We hypothesized that ASC therapy would result in systemic im-
munemodulation, reduction of the inflammatory lesions, and im-
provement of clinical signs. We found that ASCs administered
systemically resulted in complete clinical remission or substantial
clinical improvement in five of the seven cats. This improvement
was correlated with systemic immune modulation and reduced
inflammatory lesions. Cats that responded to ASC therapy had in-
creased percentages of circulating total CD8 T cells and decreased
percentages of cytotoxic CD8 T cells with low expression of CD8
(CD8lo) cells prior to therapy, suggesting that circulating CD8+
T cells and CD8 T-cell subsets may be promising biomarkers for
patient selection, monitoring response to therapy, and elucidat-
ing how ASCs modulate oral inflammation and decrease T-cell
activation.
MATERIALS AND METHODS
Study Population
This study was conducted with approval of the Institutional
Animal Care and Use Committee, and the Clinical Trials Re-
view Board, University of California, Davis. All owners signed
an informed consent. Nine client-owned cats with refractory
FCGS, nonresponsive to full-mouth tooth extractions and im-
munosuppressive therapies, were recruited to the study. In-
clusion criteria included cats affected by FCGSonly,with noother
primary comorbidities, that did not respond to full-mouth extrac-
tion performedat least 6months before enrollment. If corticoste-
roid or other immunosuppressive therapy was prescribed, it had
to be discontinued 2weeks prior to and for the entire duration of
the trial. Full-mouthdental radiographswereobtained to confirm
the absence of retained root tips and to rule out any other under-
lying pathologies. All cats were screened and tested negative for
feline immune deficiency virus and feline leukemia virus
infection.
Study Design
The study design is illustrated in Figure 1. Cats that met the inclu-
sion criteria had subcutaneous abdominal fat collected under
general anesthesia. Peripheral blood samples were obtained be-
fore treatment and at 1, 3, and 6 months after treatment for a
complete blood cell count, serum biochemistry profile, serum
protein analyses, lymphocyte phenotyping, and cytokine analy-
ses. In addition, presence of anti-bovine serum albumin (anti-
fetal bovine serum [FBS]) antibodies was evaluated before and
at 6 months after ASC administration. Oral biopsies were col-
lected before ASC administration (n = 9) and at 6months after ad-
ministration (n= 3). Clinical disease severitywas evaluatedusing a
Stomatitis Disease Activity Index (SDAI) scoring system [34]. The
SDAI scoring was performed at the time of study enrollment and
at the exit examination (supplemental online Fig.1) [34]. Briefly,
each cat’s owner completed a brief questionnaire and scored
the appetite, activity level, grooming behavior, and perceived
oral comfort on a scale of 0–3. In addition, 2 veterinary dentists
specialists (B.A., F.V.), experienced in FCGS evaluation, scored the
severity of oral inflammatory lesions as 0 (no lesion), 1 (mild),
2 (moderate), or 3 (severe). The SDAI score for each cat was cal-
culated at each time point (range: 0, no disease, to 20, severe dis-
ease). A final examination was performed at 6 months after the
first ASC treatment.
During the study period, the cats received only opioid
analgesic management (i.e., buprenorphine or oxymorphone)
without any immunosuppressive, antibiotic, or nonsteroidal
anti-inflammatory medication. To evaluate the true therapeutic
efficacy and safety of autologous ASCs administered systemically,
we elected to administer only ASCs and no additional immunosup-
pressive or antibiotic therapy during the entire 6-month period of
the study. Our outcome measures (i.e., lymphocyte subsets, in-
flammatory parameters) could all potentially be altered by steroid
therapy and would confound data analysis. In addition, as the
mechanism(s) by which ASCs heal oral tissues and alter immune
subsets is unknown, concurrent administration of immunosup-
pressive agents could alter ASC efficacy. In addition, blood from
six cats that presented to the Dentistry and Oral Surgery service
for mild dental disease was used to generate reference ranges
for variables where robust reference intervals were not available
(i.e., CD4 and CD8 numbers and serum IgA).
ASC Isolation and Expansion
ASC isolation and expansion were performed at the Regenera-
tive Medicine Laboratory at the William R. Pritchard Veterinary
Medical Teaching Hospital, according to previously established
protocols [17]. Briefly, ASCs were cultured in low-glucose
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Dulbecco’s modified Eagle’s medium (DMEM; Corning Life
Sciences, Manassas, VA, http://www.cellgro.com), 10% FBS
(HyClone Inc., Logan, UT, http://promo.gelifesciences.com), and
1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham,
MA, http://www.thermofisher.com) in tissue culture flasks
(Nunc, Roskilde, Denmark, http://www.thermofisher.com) and
incubated at 37°C in 5% carbon dioxide. Cells were passaged once
they reached approximately 70% confluence. Fresh, expanded,
early-passage cells were used for treatment (second or third
passage) and the remaining cells were cryopreserved. For the
subsequent dose (at 4 weeks after the first dose), an aliquot
of first-passage cells were thawed and cultured expanded for
72 hours to regain cell viability and function prior to infusion,
effectively using second- or third-passage cells. Cells are pro-
vided in glass vials to avoid plastic adherence while awaiting
administration.
ASC Phenotyping
Surface protein expression on fetal MSC lines was determined
using flow cytometry, as described previously [17]. All anti-
bodies were purchased from the Leukocyte Antigen Biology
Laboratory, University of California, Davis (UCD), unless other-
wise indicated. Antibodies included MHC II (42.3), CD18
(FE3.9F2), CD90 (CA1.4G8), CD44 (IM7; BioLegend, San Diego,
CA, http://www.biolegend.com), and CD105 (SN6; eBioscience,
SanDiego, CA, http://www.ebioscience.com). For unconjugated
antibodies, a mouse IgG-phycoerythrin antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA, http://www.
jacksonimmuno.com) was used for secondary labeling. Canine
CD8a (CA9.JD3), rat immunoglobulin G-allophycocyanin (IgG-
APC) (eBR2a; eBioscience), and mouse IgG-APC (MCA928; AbD
Serotec, Kidlington, Oxford, UK, http://www.abdserotec.com)
were used as isotype controls. Sampleswere run on a flow cytom-
eter (Cytomics FC500; Beckman Coulter, Brea, CA, http://www.
beckmancoulter.com). Flow cytometry data were analyzed using
FlowJo flow cytometry software (Tree Star, Ashland, OR, http://
company.flowjo.com)
Peripheral Blood Mononuclear Cell Proliferation Assay
Peripheral bloodmononuclear cell (PBMC) isolationandmixed leu-
kocyte reactionswere carriedout as describedpreviously [58]with
modifications described in this section. Histopaque 1119 (Sigma-
Aldrich, St. Louis, MO, http://www.sigmaaldrich.com) was mixed
with Ficoll-Paque (GE Healthcare, Piscataway, NJ, http://www.
gelifesciences.com) anddilutedwith tissue culturewater for a final
specific gravity of 1.066. This diluted Ficoll-Paquewas layered over
the Histopaque.Whole blood was diluted withmodified Tyrode’s/
HEPES buffer containing EDTA (12 mMNaHCO3, 138 mMNaCl,
2.9 mM KCl, 10 mM HEPES, and 1 M EDTA), and layered on top
of the diluted Ficoll-Paque layer. The blood was centrifuged
and PBMCs were collected and resuspended in activation me-
dium (DMEM plus 10% FBS plus 1% penicillin/streptomycin),
Figure 1. Images present the study design (A) and timeline (B) as well as signalment and clinical data (C). p, Animals are deceased due to un-
related causes. Abbreviations: DSH, domestic shorthair; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; neg, negative;
post, after treatment; pre, before treatment.
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and stored on ice until plating. PBMCs were activated with
5 mg/ml concanavalin A (ConA; Sigma-Aldrich). To measure
proliferation via 5-bromo-29-deoxyuridine (BrdU), cells were
collected and processed per manufacturer’s instructions
(BrdU Flow Kit; BD Biosciences, Franklin Lakes, NJ, http://
www.bdbiosciences.com), stained with a viability dye (Fixable
Viability Dye eFluor780; eBioscience), and anti-BrdU conju-
gated to Alexa Fluor647 (clone MoBU-1; Thermo Fisher Scien-
tific), and analyzed on a flow cytometer (Cytomics FC500).
Flow cytometry data were analyzed using FlowJo flow cytom-
etry software (Tree Star).
ASC Treatment
Each cat received an ASC transfusion 10–14 days after fat harvest.
All cats were admitted 1 day prior to treatment. Intravenous (i.v.)
fluid administration (lactated Ringer solution)was initiated at least
30minutes before treatment. A single dose (2mg/kg) of diphenhy-
dramine was administered subcutaneously 20 minutes before
treatment.Eachcat received2 i.v. transfusionsof203106 (approx-
imately 5 million ASCs per kg) fresh autologous ASCs. Each dose of
20 million ASCs was administered slowly, over a period of 20–
30 minutes. Each dose was drawn from the glass vial into the sy-
ringes in4separatealiquots (approximately5millioncellsata time)
just before administration to prevent ASC adherence to syringe
plastic. All catswere hospitalized for 48–72 hours after transfusion
to monitor for adverse reactions. Opioid analgesics were adminis-
tered during hospitalizationevery 8–12hours tobe consistentwith
the cat’s opioid analgesic management.
Histology and Immunohistochemistry
Oral biopsies were fixed en bloc in 10% neutral buffered forma-
lin. Transverse sections were embedded in paraffin and 5-mm
sections were cut, mounted, and stained with hematoxylin and
eosin according to standard laboratory protocols. Immunohis-
tochemistry was performed on 4-mm-thick, formalin-fixed,
paraffin-embedded tissue sections,mounted on charged slides
and air-dried overnight. Sections were deparaffinized in xy-
lene and rehydrated through graded alcohols to phosphate-
buffered saline. Endogenous peroxidases were quenched with
0.3% hydrogen peroxide for 30 minutes in methanol prior to
rehydration. Antigen retrieval was performed in Dako Target
Retrieval Solution (S1699; Agilent Technologies, Glostrup,
Denmark, http://www.dako.com) for 30 minutes at 95°C and
then cooled for 20 minutes. Sections were blocked for 20 min-
utes in 10% normal horse serum in Dulbecco’s phosphate-
buffered saline (DPBS). Primary antibodies and dilutions were:
rat anti-CD3 (clone 3-12, diluted 1:10; Leukocyte Antigen Biol-
ogy Laboratory, UCD School of Veterinary Medicine, Davis,
CA, http://www.vetmed.ucdavis.edu); and rabbit anti-CD20
(NeoMarker RB-9013-P1; 1:300; Thermo Fisher Scientific). Pri-
mary antibodies were incubated for 1 hour, rinsed, and
detected with a streptavidin-horseradish peroxidase label
(anti-rabbit link, or anti-rat link; 4+ Detection System GR608,
or GR607 and HP604, respectively; Biocare Medical, Concord,
CA, http://biocare.net). Each reagent was incubated for 10 min-
utes at room temperature, and two 3-minute rinses occurred
between each reagent application. Detection was visualized
with Vector NovaRED for peroxidase (SK-4800; Vector Labora-
tories, Burlingame, CA, http://vectorlabs.com), per the manu-
facturer’s instructions. Sections were counterstained in Mayer’s
hematoxylin. Nonspecific background was evaluated with dupli-
cate sections that received diluent in place of the primary anti-
body. Biopsies were interpreted by a board-certified veterinary
pathologist (N.V.).
Hematology and Protein Analysis
Blood sampleswere collected into potassiumEDTA vacutainers
(BD Biosciences). White blood cells, including lymphocytes,
and neutrophils, were quantified by an automated analyzer
(Bayer ADVIA 120; Bayer Diagnostics, Tarrytown, NY, http://
healthcare.bayer.com). Serum was isolated from whole blood
collected without an anticoagulant. After clotting, blood was
centrifuged (1,000g for 10 minutes) to isolate serum, and ali-
quots were stored at280°C until analyzed. Serum biochemical
profile was determined by an automated analyzer (Cobas c501;
Roche Diagnostics International, Risch, Switzerland, http://
www.roche-diagnostics.ch). Samples for serum IgA and IgG (ra-
dial immunodiffusion) and protein electrophoresis were ship-
ped on dry ice overnight to the Cornell University Veterinary
Diagnostic Laboratory (Ithaca, NY).
Cytokine Enzyme-Linked Immunosorbent Assays
Interferon-g (IFN-g), tumor necrosis factor-a (TNF-a), interleukin-
1b (IL-1b), and IL-6weremeasured in serumbeforeandat 1, 3, and
6 months after the first ASC therapy, using feline-specific enzyme-
linked immunosorbent assay (ELISA) kits (Duosets; R&D Systems,
Minneapolis, MN, http://www.rndsystems.com). ELISA kits were
run following the manufacturer’s instructions except that samples
weredilutedbyat least one-quarter in reagentdiluent todiluteout
serum effects. All ELISA samples were read on a Synergy HTMulti-
Modemicroplate readerwithGen5software (Biotek,Winooski, VT,
http://www.biotek.com).
Anti-Bovine Serum Albumin ELISA
The anti-bovine serum albumin (BSA) ELISA was adapted from
Gershwin et al. [35]. ELISA plates were coated with 1 mg of
BSA (Thermo Fisher Scientific) in 100ml of carbonate-bivarbonate
buffer (Fraction V; Thermo Fisher Scientific) in a carbonate-
bicarbonate buffer (63.5 mM carbonate, pH 9.5), overnight at
4°C. The wells were then blocked by adding 100 ml of 1% rabbit
serum albumin (Sigma-Aldrich) in DPBS (Thermo Fisher Scientific)
to each well, followed by incubation at 37°C for 1 hour. The wells
were washed with DPBS plus 0.1% Tween 20 (“wash buffer”;
EMD Millipore, San Diego, CA, www.emdmillipore.com) once for
10 minutes, followed by 6 brief washes. Feline serum samples were
diluted1:5,000 inwashbuffer andplated in triplicate (100ml perwell)
Knownnegative and highly positive feline sampleswere run as as-
say controls. Plateswere incubatedat37°C for 1hour, thenwashed
as described above. Rabbit anti-feline IgG heavy and light chain
(H&L)-HRP, 100 ml (Southern Biotech, Birmingham, AL, http://
www.southernbiotech.com) diluted 1:10,000 was added to each
well. The plates were incubated at 37°C for 1 hour, then washed
as above. Freshly prepared 3,39,5,59-tetramethylbenzidine
peroxidase substrate, 100 ml (KPL, Gaithersburg, MD. http://
www.kpl.com)was added to eachwell and plateswere incubated
at room temperature in the dark until color developed. The col-
orimetric reaction was stopped with 100 ml of 2N H2SO4, and
plates were read at 450–540 nm on a Synergy HT Multi-Mode
microplate reader with Gen5 software (Biotek). The increase
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in color relative to the negative control sample was determined
for each patient sample.
Flow Cytometry
We labeled 100 ml aliquots of whole blood (EDTA) with 25 ml
mouse anti-feline CD4 (clone FE1.7B12), CD8-a (clone FE1.10E9),
or CD21 (clone CA2.1D6) (Leukocyte Antigen Biology Laboratory).
Red blood cells were lysed with an ammonium chloride lysing
buffer (154 mM ammonium chloride, 10 mM potassium bicar-
bonate, 100 mM EDTA, pH 7.2). Cells were pelleted and washed
twice in flow buffer (DPBS with 1% equine serum [HyClone]; 5 mM
EDTA, pH7.2; and 0.01% sodiumazide). Antibodieswere detected us-
ing a phycoerythrin-conjugated donkey anti-mouse IgG H&L F(ab9)2,
diluted1:50 in flowbuffer (Jackson Immunotech). Sampleswere read
on a Beckman Coulter FC500 Flow Cytometer with Cytomics soft-
ware , and analyzed using FlowJo software (Tree Star). Approxi-
mately 20,000 events were collected within a lymphocyte scatter
gate, and cell fluorescence was analyzed for cells within this gate.
Statistical Analyses
Data analysis was performed using GraphPad Prism version 6.05
software (GraphPad Software, San Diego, CA, http://www.
graphpad.com). Statistical significance between two groups
was determined by two-tailed paired t tests (stomatitis index,
biomarkers), and between time points by two-way analysis of
variance (cytokine and T-cell phenotype analyses). The num-
ber of cats in the nonresponding group (n = 2) prohibited ac-
curate statistical analyses comparing responder cats to
nonresponders formost parameters. As such, basic descriptive
statistics were used in these situations. p values ,.05 were
considered statistically significant.
RESULTS
Feline ASCs Have a Typical MSC Surface Phenotype and
Inhibit Lymphocyte Proliferation In Vitro
Feline ASCs were uniformly positive for CD105, CD44, and CD90,
and negative for CD18 andMHCII (Fig. 2A–2E). ASCs significantly
suppressed T-cell proliferation when stimulated with ConA in
coculturewith allogeneic PBMCs (n = 5; p = .03) (Fig. 2F), asmea-
sured by BrdU incorporation.
ASC Treatment Induced Marked Clinical Improvement
in Cats With FCGS
Ninecatswereenrolled in the study; however, 2 catsdiscontinued
the clinical trial within the first 2 months of the study because of
the owner’s decision to administer corticosteroids to the cats.
Seven cats completed the study and their signalment is presented
in Figure 1. All cats had full-mouth tooth extractions and were
considered nonresponsive to any therapeutic intervention. All
had chronic, severe mucosal inflammation in the caudal oral cav-
ity and various other locations within the oral cavity, with a dis-
ease duration of 1–7 years (mean: 2.7 years). During treatment,
two cats experienced immediate transfusion reactions character-
ized by rapid respiration, urination, vomiting, and apathy. These
reactions were infusion-rate dependent and spontaneously re-
solved within 10–15 minutes, after which the transfusion was
completed at a slower rate (2 million cells per minute). No other
short- or long-term adverse reactions were noted in any of the
cats. Of the 7 cats, 5 responded to treatment and exhibited either
complete clinical remission (n = 3) or substantial clinical improve-
ment (n=2)within1–4monthsof the firstASCadministration (Fig.
3A1, 3A2, 3B1, 3B2). Two cats had either minimal or no clinical re-
sponse (Fig. 3C1, 3C2).
Clinical assessment of disease severity, by means of the SDAI,
confirmed our clinical observations (Fig. 3D, 3E). In general, the
improvement of clinical signs corresponded with improvement
of the oral mucosal lesions. The responder cats began eating
more, gaining weight, resuming grooming behavior, and resum-
ing sociability. The owners reported a return to pre-FCGS activity
levels in four responder cats and near return to pre-FCGS activity
in one responder cat. The two cats that did not respond had static
SDAI and the owners reported the same activity levels aswith his-
toric immunosuppressive therapy. Therewasno significantdiffer-
ence between responder and nonresponder stomatitis index
before treatment, indicating that clinical severity doesnot predict
response (Fig. 3D, 3E).
Clinical and Histopathologic Correlation Between
Responders and Nonresponder Cats
Oral mucosal biopsies were obtained from all cats prior to study
enrollment. Post -SC treatment oral biopsy specimens were avail-
able from one cat that achieved complete clinical remission, one
cat that exhibited substantial improvement, and one cat that did
not respond to treatment. All biopsy specimenswere analyzed his-
tologically and post-treatment biopsy specimens were compared
with the corresponding pretreatment biopsy. All cats that showed
improvement in SDAI clinical scores also exhibited improved tissue
inflammation on histopathologic examination (Fig. 4).
In all pretreatment biopsy specimens, the epithelium and
subepithelial stroma were heavily infiltrated by lymphocytes,
plasma cells, and neutrophils, with occasional Mott cells, mast
cells, and histiocytes. The surface epithelium was multifocally
ulcerated and hyperplastic, with multiple rete pegs extending
deep into the subjacent stroma. Immunohistochemistry revealed
that CD3+ cells were present within the epithelium and subepi-
thelial stroma, whereas CD20+ cells were restricted to the sub-
epithelial stroma (Fig. 4).
Upon completion of the study, a complete return to normal
tissue architecture was observed in a cat with complete clinical
remission. Rare lymphocytes were observed within subepithelial
stroma, with no evidence of epithelial hyperplasia, ulceration, or
inflammation. The absence of CD3 and CD20 lymphocytes was
confirmed by immunohistochemistry (Fig. 4A).
There was mild lymphoplasmacytic infiltration in the oral mu-
cosal sections from a cat with substantial clinical improvement.
There was no evidence of neutrophilic inflammation or ulceration.
Occasional retepegswerepresentandsuperficial stromawasmod-
erately expanded by edema. Moderate numbers of CD3+ T cells
were scattered randomly within the epithelium and the stroma,
whereas moderate numbers of CD20+ B cells were primarily lo-
cated in the subepithelial stroma (Fig. 4B).
Histologic sections of oral mucosa from a nonresponsive cat
after treatment were consistent with severe, chronic, lympho-
plasmacytic and neutrophilic ulcerative stomatitis, which was
identical to the findings before treatment. There were moderate
numbers of randomly scattered CD3+ T cells intraepithelially and
within the subepithelial stroma. The subepithelial stroma was
densely and diffusely infiltrated by CD20+ B cells (Fig. 4C).
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ASC Administration Modulates Immune Cell Subsets:
Cats With FCGS Have High Circulating CD8+ T Cells That
Normalize With Therapy
Cats with FCGS typically have systemic evidence of inflammation,
including blood neutrophilia, polyclonal hypergammaglobuline-
mia, and increasedexpressionofproinflammatoryserumcytokines
[9, 36]. The cats in this study recapitulated this phenotype.
Neutrophil countswere generally elevated above the reference in-
terval in responding cats (responders pre-injection: 10.73 1036
4.83 103; reference range: 2.03 103–9.03 103) and returned to
normal or near-normal levels within 6 months after the first injec-
tion (6months: 6.33 1036 3.03 103) (Fig. 5A), whereas nonres-
ponding cats showed no change in neutrophil number and
remained in or near the reference interval throughout the study
Figure 3. Clinical measure of disease severity. All cats had severe oral mucosal inflammation at the caudal oral cavity (A1, B1, C1). Clinical re-
sponse among the responder catswas characterized by complete clinical remission (A2) in three cats and substantial clinical improvement in two
cats (B2). No responsewasobserved in two cats (C2). The stomatitis activity disease index (SDAI)was used to score disease severity of all cats that
completed the study. (D): Table showing the SDAI scores at entry and at exit of the study with a calculation of percent recovery. Data for non-
responders are in gray and italicized type (cats 4 and 7). (E):Graph of SDAI scores at entry and exit indicating five responding cats (black circles)
and two nonresponding cats (open boxes). Abbreviations: Post, after treatment; pre, before treatment.
Figure 2. Feline adipose-derived mesenchymal stem cells (ASCs) expressed surface markers consistent with an MSC phenotype. They were
CD105+ (A), CD44+ (B), CD90+ (C), CD182 (D), andMHC II2 (E). (F): They also suppressed proliferation of activated PBMCs in mixed leukocyte
reactions experiments (n = 5; p = .03). Abbreviations: BrdU, 5-bromo-29-deoxyuridine; ConA, concanavalin A; MSC, mesenchymal stem cell;
PBMC, peripheral blood mononuclear cell.
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(pre-injection: 6.431036 2.03 103; 6months: 9.5310362.43
103) (Fig. 5A). Nonresponding cats had higher total serum globulin
levels and lower serum IgA levels than responding cats; however,
neither group showed a change after ASC therapy (Fig. 5B, 5C).
Most cats had normal percentages of circulating CD4+ T cells
(with2catshavingdecreasedpercentages) andthis didnot change
over 6months regardless of clinical response (Fig. 5D). In contrast,
in 3 of 5 cats that responded to ASC therapy, baseline circulating
CD8+ T-cell levels were elevated above the reference range (Fig.
5E), resulting in a low CD4/CD8 ratio in 4 of the 5 responder cats
at time 0 (Fig. 5F). CD8+ T cells remained high 1 month after the
first injection (responders pre-injection: 29%618.57%, non-FCGS
control group: 16% 6 4.18%). However, by 6 months post-ASC
treatment, the percentage of CD8 T cells had nearly normalized
Figure 4. Histologic and immunohistochemical evaluation of the feline chronic gingivostomatitis oral mucosa. Histomorphology of sections
from all patients pretreatment was consistent with severe lymphoplasmacytic and neutrophilic stomatitis accompanied by epithelial hypertro-
phyandmultifocal ulcerations ([A–C], H&Ecolumn). PretreatmentCD3+T cellswerepresentwithin theepitheliumandsubmucosa, andCD20+B
cells were mainly present within the subepithelial stroma. Sections obtain from a cat with complete clinical remission ([A], Post columns) had
histology consistent with normal mucosa. Histomorphology of sections from a substantial responder ([B], Post columns) was consistent with
mild lymphoplasmacytic stomatitis accompanied bymild epithelial hyperplasia and superficial stromal edema. After treatment,moderate num-
bersofCD3+T cellswereobservedwithin theepitheliumand stroma in sections formpartial responders, andmoderatenumbers of CD20+Tcells
were located in the subepithelial stroma. Histomorphology of sections obtained from a nonresponder cat after treatment ([C], Post columns)
was consistent with severe chronic lymphoplasmacytic and neutrophilic ulcerative stomatitis, which was histologically similar to treatment.
Distribution of CD3+ and CD20+ cells was similar to that observed before treatment. Scale bar = 200 mm. Abbreviations: H&E, hematoxylin
and eosin; post, after treatment; pre, before treatment.
Figure 5. Circulating inflammatory cells and serum immunoglobulins. Flow cytometric analysis of whole blood for CD4 (A), CD8 (B), and neu-
trophils (D), including the calculated ratio of CD4 to CD8 T cells (C). Globulin (E) and IgA (F) concentrations were measured in serum. (D, E):
Patterned gray bars represent standard reference intervals obtained from University of California, Davis, reference intervals. (A–C, F): Plain
gray bars represent the range values of control cats (n = 6), which were used for parameters that did not have standard reference intervals.
Abbreviations: Pre, before treatment.
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in all responder cats, with a resultant normalization of the blood
CD4/CD8 ratio by 6 months in 4 of the 5 responder cats (Fig. 5E,
5F). One of the nonresponding cats showed a consistently low
percentage of CD8 T cells and high CD4/CD8 ratio throughout.
Interestingly, this cat had a very high B-cell count in peripheral
blood samples. The other nonresponder showed higher than
normal CD8 percentage and low CD4/CD8 ratio, which did not
change throughout the study (Figs. 5E, 5F).
Increased Percentage of CD8lo Cells in the Blood of Cats
With FCGS Predicts Response to MSC Infusion
Circulating CD8+ T cells were further examined to identify a pop-
ulation of CD8+hi and a population of CD8+lo cells (Fig. 6A, 6B). A
majority (.80%) of these CD8lo cells were CD5+, confirming that
theywere CD8lo T cells (data not shown). Cats that responded to
ASC therapy had a significantly lower percentage of CD8lo cells
(as a percentage of total CD8+ T cells) than normal cats and cats
that did not respond to therapy (Fig. 6A–6C). By 6 months after
the first injection, the CD8lo population increased significantly,
such that 3 of the 5 responder catswerewithin the control range
and were no longer significantly different from the nonre-
sponders (Fig. 6D). The level of ,15% CD8lo cells in the blood
of cats with FCGS was 100% predictive of response to ASC ther-
apy in this small cohort.
CatsWith FCGS That Responded to ASC Transfusion Had
Increased Serum IL-6 Levels
The levels of the proinflammatory serumcytokines TNF-a, IL-1b,
and IFN-g were generally elevated in all cats prior to ASC trans-
fusion (Fig. 7). One of the nonresponding cats exhibited a
marked proinflammatory cytokine profile, indicative of a severe
systemic inflammatory state, throughout the study with only
IFN-g normalizing (Fig. 7). Although an outlier, we elected to in-
clude this cat, given the small number of patients in this pilot
study. The other nonresponding cat showed very low levels of
all cytokines (Fig. 7). Both IFN-g and IL-1b levels decreased in
most cats after the first ASC injection and stayed low or unde-
tectable with variable, small increases in IFN-g (n = 2) and
IL-1b (n = 1) at later time points (Fig. 7A, 7B). TNF-a was more
variable, with three responder cats showing decreased TNF-a
levels, whereas two maintained high serum concentrations
(Fig. 7C). Interestingly, the two cats that achieved complete clin-
ical cure maintained high serum TNF-a levels throughout the
study. Interestingly, serum IL-6 was unmeasurable at baseline
in all but the one proinflammatory, nonresponding outlier cat.
Response to therapy was associated with an increase in serum
IL-6 level in all responder cats by 3 months that plateaued
through the 6-month time point (Fig. 7D).
BSA Antibody Levels
Feline ASCs were cultured in FBS and, as such, we wanted to de-
termine (a) whether cats developed antibodies to BSA, the pri-
mary protein in FBS; and (b) if the development of antibodies
was associated with treatment failure. All cats had varying
amounts of BSA antibody before ASC administration; however, ti-
ters did not change after cell administration (i.e., they stayed high
or stayed low) anddidnot correlatewith the response (or absence
of a response) to ASC therapy.
DISCUSSION
This is the first study to investigate the use of ASCs for treatment
of severe oral mucosal inflammatory disease in a naturally oc-
curring animal model. We found that systemically administered
fresh, autologous ASCs can achieve cure or substantial reduction
in inflammatory lesions associatedwith FCGS, resulting in regen-
eration of the oral mucosa and improved clinical signs. Although
this safety and efficacy study did not explicitly include a no-
treatment control group, spontaneous recovery or even signif-
icant clinical improvement has never been reported in cats with
refractory FCGS. Cats that responded to therapy had a skewed
peripheral blood CD4/CD8 ratio due to increased circulating
CD8+ cells, with an increased percentage of CD8lo cells being
highly predictive of response to MSC therapy. Full clinical re-
sponse to therapywas delayed, generally took 2–4months after
the first ASC transfusion, and followed an increase in serum IL-6
concentration (and, for those cats with complete cure, a concur-
rent increase in serum TNF-a level) with a resultant normaliza-
tion of the CD4/CD8 ratio, a reduction in blood neutrophil
number, and a general reduction of the proinflammatory serum
cytokines, IFN-g and IL-1b. Transfusion reactions were rare and
were transfusion-rate dependent. Cats had varying amounts of
anti-BSA antibody before ASC administration that did not
change after cell administration and did not correlate with
the presence or absence of response to therapy.
In this study, we demonstrated that i.v. infusion of a relatively
high dose (20 million cells per cat, equivalent to approximately
5million cells per kg) of autologous ASCs is safe andwell tolerated
in cats with severe oral inflammatory disease. During cell admin-
istration, we observed rare transfusion reactions that were de-
pendent on the rate of cell administration. A safe infusion rate
was determined (2million cells perminute) that eliminated these
reactions. Cats that had transfusion reactions recovered rapidly
and were no less likely to respond to ASC treatment than those
cats that did not exhibit transfusion reactions. The reactionswere
independentof anti-BSAantibody titers.Our findings suggest that
previous FBS exposure via vaccination does not predispose ani-
mals to react to autologous i.v. stem cell injections with cells
grown in FBS-containing media. Transfusion reactions have been
previously reported in a study where cats received low doses of
ASCs [22]. However, there were differences in our studies that
might explain the relativelyminor transfusion reactionswe noted
that were easy to eliminate by slowing the transfusion. For exam-
ple, cats in the other study received a substantially lower dose of
cells; however, the cells were allogeneic, had been frozen in di-
methyl sulfoxide (DMSO)/FBS, and were not culture expanded
after cryopreservation before administration [22].
One objective of this study was to determine if a biomarker
could be found that could both predict response to ASC therapy
and help reduce the list of possible mechanism(s) by which ASCs
work to heal oral inflammation that is secondary to chronic anti-
genic stimulation and characterized by T-cell activation in tissues.
We found that circulating CD8+ T cells were elevated inmost cats
with FCGSprior to ASC treatment (hence, these cats had a skewed
CD4/CD8 ratio) and, of these CD8+ cells, very few were CD8lo. In
fact, a decreased CD8lo percentage within the CD8+ blood cells
was 100% predictive of response to ASC therapy.
CD8lo cells have been characterized in humans, mice, and
cats. These cells are associated with chronic viral infections
such as Epstein-Barr virus [37] and HIV in humans, and feline
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immunodeficiency (FIV) in cats [38–40], as well as chronic an-
tigen stimulation in a mouse skin-graft model. In cats, CD8lo
cells express CD44, CD49d, and CD18, as well as high MHCII
and low or absent CD62L, consistent with an activated pheno-
type [38–40]. They have strong anti-FIV suppressor activity [38]
and can be used as a biomarker to differentiate cats with FIV
infection from FIV-vaccinated cats [41]. Receptor expression
on CD8 cells may dictate whether a CD8 cell has a suppressive
or cytotoxic phenotype. Decreased receptor expression of CD8
limits the ability of cells to be classically activated to a cytotoxic
phenotype and increases suppressive functions. These CD8lo
cells likely represent a subset of activated CD8 effector/
suppressor cells capable of downregulating the activation of
naı¨ve T cells and resulting from repeated and/or continuous ex-
posure to self-antigen. The decreased percentage of CD8lo cells
in catswith FCGS that responded toASC therapymay imply that
these cats have decreased suppressor function and that ASC
administration supports the expansion of CD8lo cells helping
to resolve the inflammatory oral response. In nonresponders,
these cells are not lacking before treatment and, thus, ASCs do
not induce a response via this mechanism.
ASC administration resulted in complete clinical remission or
substantial clinical improvement in five of seven cats with FCGS
that completed the study. This clinical improvement was associ-
atedwithhistologic clearingof bothCD3+Tcells andCD20+Bcells
from the lesions of responder cats. If we had screened for CD8
predominance in blood and a concurrent decrease in CD8lo cells,
we could have predicted with 100% accuracy the response to
therapy in this small cohort of cats. The elevation of CD8+
T cells found in circulation support the theory that FCGS is an in-
appropriate response to chronic, oral, antigenic stimulation from
clinical/subclinical viral infections [11–14]. In the case of FCGS, it
is likely that CD8+ T cells are contributing to the inflammatory le-
sions, andweobserve correlation between the reduction of CD8+
T cells in circulation and the reduction in clinical signs and histo-
logicmarkersof inflammation.ApredominanceofCD8+T cells has
been reported previously, suggestive of an underlying cytotoxic
cell-mediated immune response [9].We did not collect frozen tis-
sue samples in this cohort of cats; therefore, we were unable to
discriminate between CD4+ and CD8+ tissue cells in this study.
Our data suggest thatASC administration to catswith FCGShas
immunomodulatory effects. Aside from the reduction in CD8+
T cells, responding cats showa reduction in the systemic inflamma-
tory response following ASC treatment, including reduced levels of
circulating neutrophils and serum IFN-g and IL-1b. The cats that
respondedwith complete clinical remission showed a sustained in-
crease in serum TNF-a levels and all responder cats showed eleva-
tion in serum IL-6 concentration. IL-6 is a pleiotropic cytokine
involved in pro- and anti-inflammatory processes [42]. In humans,
IL-6 induces IL-21 production under Th1 priming conditions, which
promotes Th17 differentiation [43–45]. However, IL-21 also pro-
motes IL-10 secretion and inhibits IFN-g production in the
Figure 6. Low numbers of a subset of CD8+ cells (CD8lo) predict response to adipose-derived mesenchymal stem cell (ASC) therapy and nor-
malize after treatment. CD8+ T cells can be divided into CD8hi and CD8lo populations. (A–C): Representative flow cytometry gating scheme for
CD8+ and CD8lo populations for (A) control non-FCGS cat, (B) responder feline chronic gingivostomatitis (FCGS)-affected cat, and (C) nonre-
sponder FCGS-affected cat, including the percent of total lymphocytes that were CD8+, and the percent of CD8+ cells that were CD8lo. (D):
Summary of CD8lo percentages of CD8+ cells based on flow cytometry gates described in (A–C) for all cats in the study. Responder cats had
a lower percentage of CD8lo cells before ASC treatment than at 6 months after (multiple comparisons 2-way analysis of variance, p , .05).
(E):Comparisonof thepercent ofCD8+ cells thatwereCD8lo in responder andnonresponder groupsbeforeASC treatment foruse as abiomarker
topredict response to treatment. Responders hada lowerpercentageofCD8+cells thatwereCD8lo thannonresponders (unpaired t test,p= .04).
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developing Th17 cells, preventing the generation of pathogenic
Th1/Th17 effector cells. IL-21 also inhibits the differentiation of
CD8+T cells. This inhibitionofexcessiveCD8+T-cell differentiation,
leading to functional T-cell exhaustion, may be important for the
protective role of IL-21 in chronic viral infections [46–50].
IL-6 is a major regulator of the balance between regulatory
T cells (Tregs) and effector Th17 cells [51]. Th17 cells are key play-
ers in the pathogenesis of autoimmune diseases, whereas Tregs
maintain tolerance and restrain excessive effector T-cell re-
sponses [51]. IL-6, together with transforming growth factor
(TGF)-b, induces Th17 cells, whereas IL-6 inhibits TGF-b-induced
Treg differentiation [52–56]. However, this effect of IL-6 seems to
be restricted to the development of na¨ıve CD4 T cells, whereas
transgenic mice in which serum IL-6 levels are constitutively ele-
vated actually have more Foxp3+ natural Tregs than nontrans-
genic mice, and those Tregs normally suppress proliferation of
na¨ıve T cells in vitro [57]. Hence, in the context of chronic immune
activation, this function of IL-6 is likely more relevant. ASCs con-
stitutively express TGF-b, whereas IL-6 is expressed upon activa-
tion with phytohemagglutinin [58]. IL-6 is secreted by ASCs from
all species tested todate, including horses, dogs, and cats [58, 59].
Ongoing work in our laboratory is focused on both in vitro and in
vivo exploration of Th17 and Treg cells in cats.
Clinical trials using MSC products have often favored frozen
aliquots of allogeneic cells for trials focused on chronic inflam-
matory lesions or acute ischemic lesions because of the relative
ease of US Food and Drug Administration approval for “lots” of
frozen cells and the advantage of an “off-the-shelf” product that
can be administered without the lag time associated with cell
expansion. Recently, however, it has been shown that 2–3 days
of culture and stem cell expansion for patients receiving alloge-
neic stem cell transfusionsmay increase cell viability and cell ac-
tivation readiness [60]. In addition, the use of DMSO as a
cryoprotectant may account for the higher incidence of transfu-
sion reactions seenwith frozen cells andpotentially interferewith
therapeutic outcomes [60, 61]. Our group favors fresh cells to fro-
zen cells for therapeutic administration and we believe much of
our efficacy data in cats with FCGS and in other ongoing clinical
trials are related to the infusion of freshly expanded cells.
There remains controversy and a paucity of data, in any given
species, to support the use of autologous versus allogenic stem
cells in terms of efficacy and outcome [60, 61]. There is some ev-
idence that i.v. administration of humanMSCs may induce an in-
flammatory cell response [62–64] and it has been shown in
horses that completely unmatched allogeneic cell infusion can
result in anti-MSC antibody production, although the signifi-
cance of antibody development is not known [25]. Although
the convenience and practicality of using allogeneic cell sources
for treatment in the clinical setting is attractive,weelected touse
autologous cells as our first line of therapy to maximize the po-
tential for efficacy while minimizing interference from an im-
mune response. In our hands, the autologous cells were safe
and efficacious for this particular disease process and, given that
the disease is chronic, the time needed for cell expansion does
not hinder patient health. Additional investigation using fresh,
allogeneic cells to treat this disease is ongoing. It appears that
theuseof allogeneic cellsmaybepermissible in someanimal spe-
cies, even when administered systemically, whereas the use of
allogeneic cells may be less feasible in other species. As with
the issue of fresh versus frozen stem cells, there is a lack of
long-term, randomized, placebo-controlled studies to make de-
finitive statements. However, as FCGS is a common disease with
limited therapeutic options, approaching these questions in a
naturally occurring model of disease becomes practical.
Response toASC therapywasoftendelayedbyup to4months
after the first injection, even in cats who fully responded. This
Figure 7. Plots of serum cytokine data. Serum cytokines were variably detectable in all cats in the study. Enzyme-linked immunosorbent assay
results for serum levels of IL-6 (A), IFN-g (B), TNF-a (C), and IL-1b (D). Note that one nonresponder showed very high expression of most serum
cytokines, indicating a severe systemic proinflammatory state. Abbreviations: IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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delayed response may be due to ASCs acting through a systemic
mechanism that prevents activation of new T cells or slowly pro-
vides regulatory signals to activated cells, which would then re-
veal clinical response only as activated pathogenic cells undergo
apoptosis or reach an exhausted state. This delayed response is
important for clinicians to note to avoid a premature conclusion
that therapy was ineffective.
CONCLUSION
In summary, the i.v. injection of ASCs in cats diagnosed with FCGS
that havenot responded to conventional therapy is safeand.70%
effective. Cell therapy was most effective in cats with decreased
percentages of blood CD8lo cells. Successful ASC therapy resulted
in (a) complete clinical remission or reduction in clinical disease se-
verity, (b) histologic resolution of the oral lesions, (c) reduction of
total circulating CD8+ T cells (and increased CD8lo cells), (d) resolu-
tion of neutrophilia and reduction of serumproinflammatory cyto-
kine concentrations (IL-1b and IFN-g), and (e) increases in serum
IL-6 levels. Although the full mechanisms by which ASC treatment
reduces inflammation in this model remain to be elucidated, this
study demonstrates the clinical potential of ASC therapy for oral
inflammatory lesions characterized by CD8+ cells and T-cell activa-
tion. We also identified a potentially useful biomarker that could
both dictate patient enrollment (decreased percentage of CD8lo
cells) as well as shed light on themechanisms by which ASCsmod-
ulate healing in these inflammatory lesions. These results are en-
couraging both for the treatment of a refractory, severe lesion in
cats, and as a potentially translatable therapy for the treatment
of human oral inflammatory disease.
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